Jane Sanders is a Director and founding member of AV7 Ltd which was formed in 2005 to exploit in vivo applications of thyroid stimulating and thyroid blocking monoclonal antibodies. She joined RSR Ltd in 1993 and is currently a Director of RSR Ltd and the Deputy Director of RSR's FIRS Laboratories where she heads a team of scientists working on the TSH receptor and TSH receptor autoantibodies.  She has a PhD from the University of Bath and over 100 peer reviewed articles in the scientific literature. 

In 2002, Jane's team produced M22™, the first human monoclonal thyroid stimulating autoantibody with the characteristics of patient serum TSHR autoantibodies. In addition to its important use in structural and functional studies of the TSHR, M22™ is now used in fully automated assays for TSHR autoantibodies making their detection available routinely worldwide. 

Also, in 2008 Jane's team produced the blocking type human monoclonal TSHR autoantibody K1-70™.  K1-70™ is very effective at blocking the stimulating actions of TSHR autoantibodies and of TSH in vitro and in vivo.  Ongoing clinical trials indicate K1-70™ will be an effective new drug to block TSHR activation.

Jane’s team have used cryo-electron microscopy to solve the structure of the full length TSHR in complex with K1-70™ (2022) followed by the structures of other blocking and stimulating human autoantibodies in complex with the TSHR. These structures have allowed the elucidation of the mechanism of action of TSHR autoantibodies on the TSHR at the atomic level.

She is a member of the European Thyroid Association, British Thyroid Association, Society for Endocrinology and American Thyroid Association and has given many invited talks to learned societies over the past 30 years.